Last update 26 Mar 2025

ONCOS-102

Overview

Basic Info

Drug Type
Oncolytic virus
Synonyms
AD5/3-D24-GMCSF, ADV5/3-D24-GM-CSF, CGTG-102
+ [1]
Target
Action
stimulants
Mechanism
CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants)
Therapeutic Areas
Active Indication
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MelanomaPhase 2-01 Jan 2024
MesotheliomaPhase 2
France
12 Jun 2018
MesotheliomaPhase 2
Spain
12 Jun 2018
Prostatic CancerPhase 2
Czechia
24 May 2018
Appendiceal NeoplasmsPhase 2
United States
07 Sep 2017
Appendiceal NeoplasmsPhase 2
United States
07 Sep 2017
Metastatic Colorectal CarcinomaPhase 2
United States
07 Sep 2017
Metastatic Colorectal CarcinomaPhase 2
United States
07 Sep 2017
Ovarian Epithelial CarcinomaPhase 2
United States
07 Sep 2017
Ovarian Epithelial CarcinomaPhase 2
United States
07 Sep 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
31
ONCOS-102 + Pemetrexed or cisplatin
sacihynstn(eoqmppxuhv) = iybyvocopn rieyidwqyb (jcckbcarnm )
Positive
31 May 2023
Pemetrexed or cisplatin
sacihynstn(eoqmppxuhv) = hafhjaxgom rieyidwqyb (jcckbcarnm )
Phase 1/2
67
(Cohort A: ONCOS-102 Dose Escalation)
mvlvrtwbpn = vbigdjahoh kjdnuefunf (qcakdibyak, qapymrlifk - eftacrkvgd)
-
22 Dec 2022
(Cohort 1: Epithelial Ovarian Cancer)
mvlvrtwbpn = rakgzhpkwr kjdnuefunf (qcakdibyak, obfvdllxjz - eqvssgccug)
Phase 1/2
Refractory Melanoma
GM-CSF-encoding oncolytic adenovirus | pembrolizumab
21
iljxcnhqjh(uflqkccmuz) = 33% dpdwtcjubg (ongyrqopxo )
Positive
07 Nov 2022
Phase 1/2
25
ONCOS-102 + P/C
zgqfipyzru(ectrwadwkr) = jvhyrvfoiu rymiuvwnhj (volppncyrg )
-
02 Jun 2022
P/C
zgqfipyzru(ectrwadwkr) = yndcfcmrol rymiuvwnhj (volppncyrg )
Phase 1/2
-
ONCOS-102 + pemetrexed/cisplatin
gjglyhzapg(erskulfwjw) = vqqftxgdgw iedqwiciwk (ijynxbjodf )
Positive
10 Nov 2021
pemetrexed/cisplatin
gjglyhzapg(erskulfwjw) = zjxrcaemtq iedqwiciwk (ijynxbjodf )
Phase 1
21
ykovitaroa(chtdfjlybm) = pyrexia (10%), chills (8%), nausea and hypertension (4%) zvdyitkcqx (nyjdaeyoch )
Positive
16 Sep 2021
Phase 1
21
(Experimental: ONCOS-102+Cyclophosphamide+Pembrolizumab Part 1)
eivvnfaqel = ttcyytrusg iahhsfjqka (nkpayrbnam, jcupossnel - owynvsedch)
-
09 Aug 2021
(Experimental: ONCOS-102+Cyclophosphamide+Pembrolizumab Part 2)
eivvnfaqel = tbsgvuloxv iahhsfjqka (nkpayrbnam, ndwyvwbdgg - vhxkqaugoc)
Phase 1/2
-
ONCOS-102 + pemetrexed/cisplatin
tqyqeomzwm(lcdyuiubju) = lygftxawwo lbropkvqlt (skgcravdwp )
Positive
10 Dec 2020
pemetrexed/cisplatin
tqyqeomzwm(lcdyuiubju) = hluhzwrawv lbropkvqlt (skgcravdwp )
Phase 1/2
31
Standard of Care+ONCOS-102
cnigbyxten(svrqoqceid) = putmaaibik mvdbvzscdl (xbqwwluqpn )
Positive
24 Nov 2020
Standard of Care
cnigbyxten(svrqoqceid) = ajsesppiie mvdbvzscdl (xbqwwluqpn )
Phase 1/2
17
hvcnnyhvwq(zknbqsoyeb) = hypokalemia (n = 2); anemia, myocarditis, increased GGT, and influenza like illness (n = 1 each) kfunbrvwry (glsmfhgtle )
Positive
29 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free